CAP, Hospitalized
[Am J Respir Crit Care Med 2019;200: e45-67, NICE guideline]
- Calculation of CRB-65, CURB-65 score, or Pneumonia Severity Index (PSI) is recommended to help determine severity, site of care and mortality risk.
- Investigations:
- CBC with differential, random glucose, electrolytes, creatinine, ALT
- Chest x-ray, PA and lateral
- Sputum Gram stain and C&S for patients with productive cough. For organism - specific recommendations, see Treatment of Culture-proven Pneumonia
- Blood cultures
- Nasopharyngeal (NP) swab/aspirate for respiratory virus PCR
- Sputum/NP sample for M. pneumoniae, C. pneumoniae, Legionella PCR.
- Legionella pneumophila urine antigen if severe CAP or epidemiological risk
- Consider mycobacterial/fungal culture if relevant history/travel, and PCP (P. jirovecii) in immunocompromised.
- Arterial blood gas on room air, or on baseline O2 if patient receiving chronic oxygen
- Antibiotic therapy should be administered as soon as possible after the diagnosis is considered likely. This is especially important in the elderly.
Nonsevere
Usual PathogensS. pneumoniae
H. influenzae
S. aureus
Group A Streptococci
Enterobacterales
Legionella spp
Chlamydia pneumoniae
Therapy | Dose | Duration |
---|---|---|
Ceftriaxone | 1g IV daily | 3-5 days |
If CRB-65 score 1 and significant co-morbidity, or CRB-65 score 2, add:
|
||
[Azithromycin | 500mg IV/PO daily | 3 days |
or | ||
Clarithromycin | 500mg PO bid or | |
XL 1g PO daily | ||
or | ||
200mg PO once, then | ||
|
100mg PO bid |
|
Alternative
Therapy | Dose | Duration |
---|---|---|
Levofloxacin IV/PO | 750mg PO/IV daily |
Severe
- See criteria below, or based on clinical judgement and guided by CRB-65 score 3 or 4 or CURB-65 3-5 or PSI score IV or V.
Severe CAP = 1 major criterion or 3 or more minor criteria:
Major criteria:
- septic shock requiring vasopressors
- respiratory failure requiring mechanical ventilation
Minor criteria:
- respiratory rate ≥ 30 breaths/minute
- PaO2 /FiO2 ratio ≤ 250
- multilobar infiltrates
- confusion/disorientation
- urea > 7mmol/L
- leukopenia (< 4 x 109/L)
- thrombocytopenia (< 100 x 109/L)
- hypothermia (< 36°C)
- hypotension requiring aggressive fluid resuscitation
- If deterioration or persistent respiratory/systemic symptoms, consider the following etiologies (depending on epidemiologic setting/risk factors):
- Viral pneumonia, including influenza, SARS-CoV-2, and Hantavirus
- Legionella spp
- Mycobacterium tuberculosis
- Chlamydophila psittaci
- Coxiella burnetti (Q fever)
- Francisella tularensis (tularemia)
- Endemic fungi (Histoplasma capsulatum, Coccidioides immitis, Cryptococcus neoformans, Blastomyces spp)
- Pneumocystis jirovecii
Corticosteroid therapy
- Routine use of corticosteroids in severe CAP not recommended, unless associated with refractory septic shock.
Antibiotic therapy
- The standard of care is with a β-lactam + macrolide. Combination therapy is associated with decreased mortality.
S. pneumoniae
H. influenzae
S. aureus/MRSA
Group A Streptococci
Enterobacterales
Legionella spp
Chlamydia pneumoniae
Uncommon:
Consider viral:
Therapy | Dose | Duration |
---|---|---|
Ceftriaxone | 1g IV daily | |
+ | ||
Azithromycin | 500mg IV daily |
If MRSA suspected, add:
Therapy | Dose | Duration |
---|---|---|
25-30mg/kg IV once then 15mg/kg IV q8-12h | 7 days (minimum 14 days for confirmed MRSA bacteremia) | |
or | ||
Linezolid | 600mg IV/PO q12h | 7 days (minimum 14 days for confirmed MRSA bacteremia) |
If P. aeruginosa suspected:
Therapy | Dose | Duration |
---|---|---|
Piperacillin-tazobactam | 4.5g IV q6h | 7 days |
+ | ||
Azithromycin | 500mg IV daily | 3-5 days |
Ceftriaxone allergy
Therapy | Dose | Duration |
---|---|---|
Levofloxacin | 750mg IV daily | |
If MRSA suspected, add: | ||
Vancomycin | 25-30mg/kg IV once then 15mg/kg IV q8-12h | 7 days (minimum 14 days for confirmed MRSA bacteremia) |
or | ||
Linezolid | 600g IV/PO q12h | 7 days (minimum 14 days for confirmed MRSA bacteremia) |